We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Health, Inc. (HIMS) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Read MoreHide Full Article
In the latest close session, Hims & Hers Health, Inc. (HIMS - Free Report) was down 1.73% at $32.96. The stock's performance was behind the S&P 500's daily loss of 1.44%. On the other hand, the Dow registered a loss of 0.09%, and the technology-centric Nasdaq decreased by 2.22%.
The company's shares have seen an increase of 41.22% over the last month, surpassing the Medical sector's gain of 0.57% and the S&P 500's gain of 0.08%.
Market participants will be closely following the financial results of Hims & Hers Health, Inc. in its upcoming release. The company's upcoming EPS is projected at -$0.06, signifying a 135.29% drop compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $689.49 million, up 26.55% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.23 per share and a revenue of $2.9 billion, representing changes of -143.4% and +23.72%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Hims & Hers Health, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Right now, Hims & Hers Health, Inc. possesses a Zacks Rank of #5 (Strong Sell).
With respect to valuation, Hims & Hers Health, Inc. is currently being traded at a Forward P/E ratio of 638.86. This expresses a premium compared to the average Forward P/E of 23.62 of its industry.
Investors should also note that HIMS has a PEG ratio of 47.94 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. By the end of yesterday's trading, the Medical Info Systems industry had an average PEG ratio of 1.88.
The Medical Info Systems industry is part of the Medical sector. This group has a Zacks Industry Rank of 160, putting it in the bottom 35% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Hims & Hers Health, Inc. (HIMS) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the latest close session, Hims & Hers Health, Inc. (HIMS - Free Report) was down 1.73% at $32.96. The stock's performance was behind the S&P 500's daily loss of 1.44%. On the other hand, the Dow registered a loss of 0.09%, and the technology-centric Nasdaq decreased by 2.22%.
The company's shares have seen an increase of 41.22% over the last month, surpassing the Medical sector's gain of 0.57% and the S&P 500's gain of 0.08%.
Market participants will be closely following the financial results of Hims & Hers Health, Inc. in its upcoming release. The company's upcoming EPS is projected at -$0.06, signifying a 135.29% drop compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $689.49 million, up 26.55% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.23 per share and a revenue of $2.9 billion, representing changes of -143.4% and +23.72%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Hims & Hers Health, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Right now, Hims & Hers Health, Inc. possesses a Zacks Rank of #5 (Strong Sell).
With respect to valuation, Hims & Hers Health, Inc. is currently being traded at a Forward P/E ratio of 638.86. This expresses a premium compared to the average Forward P/E of 23.62 of its industry.
Investors should also note that HIMS has a PEG ratio of 47.94 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. By the end of yesterday's trading, the Medical Info Systems industry had an average PEG ratio of 1.88.
The Medical Info Systems industry is part of the Medical sector. This group has a Zacks Industry Rank of 160, putting it in the bottom 35% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.